Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ginkgo Bioworks Holdings ( (DNA) ) has shared an announcement.
On April 3, 2026, Ginkgo Bioworks, Inc., a subsidiary of Ginkgo Bioworks Holdings, completed the sale of all equity interests in Ginkgo Biosecurity, LLC to Tower Biosecurity, Inc., also known as Perimeter Systems, in exchange for a roughly 20% equity stake in the purchaser. The divested assets represented substantially all of Ginkgo’s biosecurity segment, marking a strategic shift whereby historical biosecurity results will be reported as discontinued operations, with unaudited pro forma financial statements re-presenting 2023–2025 results and the 2025 balance sheet as if the deal had been effective from January 1, 2023.
Following the transaction, Ginkgo will classify the biosecurity business as discontinued operations starting with its March 31, 2026 quarter, and has issued unaudited pro forma condensed consolidated financials reflecting the elimination of biosecurity results and related asset transfers. Management notes that a transition services agreement with Tower Biosecurity is in place but not material or recurring, suggesting the company is pivoting away from operating the biosecurity segment while retaining an equity interest and focusing its core reporting on the remaining businesses.
The most recent analyst rating on (DNA) stock is a Sell with a $6.00 price target. To see the full list of analyst forecasts on Ginkgo Bioworks Holdings stock, see the DNA Stock Forecast page.
Spark’s Take on DNA Stock
According to Spark, TipRanks’ AI Analyst, DNA is a Neutral.
The score is held down primarily by weak financial performance (shrinking revenue, large losses, and ongoing cash burn) and a bearish technical setup (price well below key moving averages with negative MACD). The latest earnings call adds support via improved cost discipline, cash-burn guidance, and notable autonomous-lab traction, but uncertainty around near-term revenue visibility and continued losses keeps the overall score below average.
To see Spark’s full report on DNA stock, click here.
More about Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings, Inc. operates in the biotechnology sector, focusing on cell programming and related bioengineering services through various business segments, including a now-divested biosecurity arm. The company structures its activities through subsidiaries such as Ginkgo Bioworks, Inc. and Ginkgo Biosecurity, LLC, and reports consolidated financial results to public-market investors.
Average Trading Volume: 1,149,081
Technical Sentiment Signal: Sell
Current Market Cap: $421.5M
Learn more about DNA stock on TipRanks’ Stock Analysis page.